Coherus Biosciences' Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia
Shots:
- Udenyca’s (Pegfilgrastim biosimilar) EU approval is based on the data demonstrating its PK and PD- for reducing the chances of infection by febrile neutropenia
- This biosimilar is currently under the US FDA inspection and has provided a PDUFA date 3 Nov- 2018. Udenyca is currently not available for commercial sale
- Udenyca (pegfilgrastim-cbqv/CHS-1701)- is a growth-colony-stimulating-factor and a long-acting form of filgrastim that stimulates the production of WBCs and stem cells
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
